$PGNY

Cummings Melissa B sold $71K of PGNY

Cummings Melissa B (Chief Operating Officer) sold 2,244 shares of Progyny, Inc. (PGNY) at $31.60 on 2026-07-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cummings Melissa B
Published Jul 16, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PGNY
Neutral
high confidence
Mentioned
$PGNY
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGNYNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not include new guidance, litigation, financing, or operational milestones.

02

Market read

Traders may note insider selling, but the 10b5-1 pre-arranged nature and modest dollar value limit trading impact.

03

What to watch

The sale size ($70.9K) is relatively small versus typical institutional flows, and the 10b5-1 structure suggests timing is pre-set rather than information-driven.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-16, disclosing a 2026-07-14 insider sale.

Background

The article is a SEC Form 4 insider transaction disclosure for Progyny, Inc.

Company-level read

Ticker impact

$PGNYNeutralHigh confidence
Context

Progyny COO Melissa B Cummings sold 2,244 shares on 2026-07-14 under a pre-arranged 10b5-1 plan, totaling about $70.9K.

Expected impact

Low likelihood of a sustained price move based solely on this Form 4 sale.

Evidence & confidence

The filing specifies an open-market sale code S and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific and not tied to operational or regulatory developments.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so some traders may treat it as a mild negative sentiment input.

Key entities

  • Progyny, Inc.

    Company whose COO insider sale is disclosed via SEC Form 4.

  • Melissa B. Cummings

    Chief Operating Officer who sold 2,244 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

$PGNYMed

Progyny at Wells Fargo healthcare conference: growth runway stays wide

Progyny (PGNY) presented at the Wells Fargo Healthcare Conference, noting seasonal August softness but expecting a September recovery. The company serves 7.2M lives, with a large addressable market. It adjusted 2024 guidance downward but emphasized long-term growth, new product lines, and strong cash flow. Management highlighted Progyny's leading position in fertility benefits and expansion into women's health. The stock is trading below its Fair Value, with a PEG ratio of 0.46, according to Inv

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

$PGNYHigh

This fertility benefit business is set to boom. Buy the stock now, Wells Fargo says

Wells Fargo initiated coverage of Progyny with an overweight rating and $37 price target, implying 45% upside. The analyst cited demographic trends, corporate wellness focus, and healthcare innovation as drivers. Progyny's market share growth, global expansion, and new offerings were highlighted. Nine of 11 analysts rate the stock a buy or strong buy, with shares up 13% over the past year.